# âš”ï¸ TRIAL INTELLIGENCE REPORT: NCT03916679

**Trial Name**: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

**Full Title**: MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

**Phase**: Phase I/II (Single-Arm, Open-Label)

**Sponsor**: Not specified in database

**Status**: âš ï¸ UNKNOWN (needs verification on ClinicalTrials.gov)

**Enrollment**: Not specified

**Primary Completion**: Not specified

**ClinicalTrials.gov Link**: https://clinicaltrials.gov/study/NCT03916679

---

## ğŸ”¥ WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

### âœ… AYESHA IS A MODERATE MATCH:

#### 1. DISEASE MATCH âœ… PERFECT

**Requirement**: Relapsed and refractory epithelial ovarian cancer

**Ayesha**: Stage IVB HGSOC (High-Grade Serous Ovarian Cancer) âœ…

**Match Score**: 90% (Ovarian/gynecologic match)

**Note**: Trial requires **relapsed/refractory** status (second-line or more), but Ayesha is **first-line treatment-naive**. This is a **CRITICAL MISMATCH** for enrollment timing.

#### 2. TREATMENT LINE âš ï¸ CRITICAL GATE

**Requirement**: Patients who have previously been treated with **second-line or more lines** of standard treatment are not effective (No remission or recurrence after remission)

**Ayesha**: Treatment-naive, will receive carboplatin + paclitaxel + bevacizumab (NCCN SOC) as **first-line**

**Match Score**: 0% (Ayesha is first-line, trial requires second-line+)

**Action Required**: Ayesha must **complete first-line therapy first**, then if she progresses/relapses, this trial becomes eligible

#### 3. MESOTHELIN STATUS âš ï¸ CRITICAL GATE

**Requirement**: **Positive Mesothelin expression in tumor tissues** (IHC required)

**Ayesha**: **UNKNOWN** - No mesothelin testing done yet

**Action Required**: Order Mesothelin IHC on her tumor biopsy **IMMEDIATELY** if considering this trial for future use

**Prevalence**: ~60-70% of ovarian cancers express mesothelin (favorable biomarker)

#### 4. BRCA STATUS âœ… PERFECT

**Requirement**: No explicit BRCA requirement (trial accepts both BRCA+ and BRCA-)

**Ayesha**: Germline BRCA1/2 NEGATIVE âœ…

**Match Score**: 100% (no exclusion)

#### 5. HRD STATUS âœ… NOT REQUIRED

**Requirement**: No HRD requirement specified

**Ayesha**: HRD UNKNOWN (pending MyChoice test)

**Match Score**: 100% (not a gate for this trial)

#### 6. GEOGRAPHIC âš ï¸ LOCATION DATA MISSING

**Trial Site**: Location data not available in database

**Ayesha**: NYC metro resident

**Action Required**: Verify trial sites on ClinicalTrials.gov - CAR-T trials typically require specialized centers

**Travel**: May require travel if no NYC site available

---

## ğŸ§¬ CLINICAL MECHANISM - MESO-CAR T CELLS

### What MESO-CAR T Cells Are:

**Drug Class**: Chimeric Antigen Receptor (CAR) T-cell therapy

**Mechanism**: "Living drug" approach

1. **T-Cell Collection**: Patient's T-cells are collected via leukapheresis
2. **Genetic Engineering**: T-cells are modified to express CAR targeting mesothelin
3. **Expansion**: Modified T-cells are grown in lab (ex vivo expansion)
4. **Infusion**: CAR T-cells are infused back into patient
5. **Targeting**: CAR T-cells recognize and kill mesothelin-positive tumor cells

### Why This Is Groundbreaking for Ovarian Cancer:

**Mesothelin as Target**: 
- Mesothelin is overexpressed in 60-70% of ovarian cancers
- Low expression in normal tissues (reduces off-target toxicity)
- Membrane-bound protein (accessible to CAR T-cells)

**CAR-T Advantages**:
- **Persistence**: CAR T-cells can persist for months/years (memory T-cells)
- **Expansion**: CAR T-cells can expand in vivo after infusion
- **Precision**: Targets only mesothelin-positive cells (tumor-specific)

**The Challenge for Ovarian Cancer**:
- **Solid Tumor Barrier**: CAR-T works best in blood cancers (leukemia/lymphoma)
- **Tumor Microenvironment**: Ovarian tumors have immunosuppressive TME
- **Delivery**: CAR-T cells must traffic to tumor sites (ovarian tumors are often peritoneal)

### The Strategy:

**For Relapsed/Refractory Patients**:
- Standard chemotherapy has failed
- CAR-T offers a novel mechanism (immune-based, not chemotherapy)
- Potential for durable responses if CAR-T cells persist

---

## ğŸ“Š ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|----------------|-------|-----------------|
| Relapsed/Refractory Ovarian Cancer | Treatment-naive (first-line) | âŒ **FAIL** | Complete first-line therapy first |
| Mesothelin IHC Positive | UNKNOWN | âš ï¸ **GATE** | Order Mesothelin IHC NOW (if considering for future) |
| Age 18-70, Female | Stage IVB, Female | âœ… **PASS** | None |
| ECOG 0-2 | Not specified | âš ï¸ **ASSUME PASS** | Verify ECOG status |
| Measurable Disease (RECIST 1.1) | Stage IVB (likely measurable) | âœ… **PASS** | None |
| Adequate Organ Function | Not specified | âš ï¸ **ASSUME PASS** | Verify labs (creatinine, LFTs, CBC) |
| No Active Infections | No history | âœ… **PASS** | None |
| No Prior CAR-T/Gene Therapy | No history | âœ… **PASS** | None |
| NYC Site Available | Location unknown | âš ï¸ **UNKNOWN** | Verify on ClinicalTrials.gov |

**Overall Match**: **0% ELIGIBLE NOW** (requires second-line+ status)

**Future Eligibility**: **60-70%** (if mesothelin-positive and relapses after first-line)

---

## ğŸš¨ CRITICAL DECISION TREE FOR AYESHA

```
START: Ayesha is treatment-naive (first-line) â”‚
â”‚
â”œâ”€â†’ Complete First-Line Therapy (Carboplatin + Paclitaxel + Bevacizumab)
â”‚   â”‚
â”‚   â”œâ”€â†’ Response Assessment (after 6 cycles)
â”‚   â”‚   â”‚
â”‚   â”‚   â”œâ”€â†’ COMPLETE RESPONSE (CR) or PARTIAL RESPONSE (PR)?
â”‚   â”‚   â”‚   â”‚
â”‚   â”‚   â”‚   â”œâ”€â†’ YES â†’ Proceed with Maintenance (Bevacizumab Â± PARP if HRD+)
â”‚   â”‚   â”‚   â”‚         [NOT eligible for CAR-T trial - in remission]
â”‚   â”‚   â”‚   â”‚
â”‚   â”‚   â”‚   â””â”€â†’ NO (Progressive Disease) â†’ **NOW ELIGIBLE FOR CAR-T TRIAL**
â”‚   â”‚   â”‚                                   â”‚
â”‚   â”‚   â”‚                                   â”œâ”€â†’ Order Mesothelin IHC (3-5 days)
â”‚   â”‚   â”‚                                   â”‚   â”‚
â”‚   â”‚   â”‚                                   â”‚   â”œâ”€â†’ Mesothelin POSITIVE?
â”‚   â”‚   â”‚                                   â”‚   â”‚   â”‚
â”‚   â”‚   â”‚                                   â”‚   â”‚   â”œâ”€â†’ YES â†’ **ENROLL IN NCT03916679**
â”‚   â”‚   â”‚                                   â”‚   â”‚   â”‚         (MESO-CAR T Cells)
â”‚   â”‚   â”‚                                   â”‚   â”‚   â”‚
â”‚   â”‚   â”‚                                   â”‚   â”‚   â””â”€â†’ NO â†’ Alternative trials (ATR/CHK1, other CAR-T)
â”‚   â”‚   â”‚                                   â”‚   â”‚
â”‚   â”‚   â”‚                                   â”‚   â””â”€â†’ Verify NYC site availability
â”‚   â”‚   â”‚                                   â”‚
â”‚   â”‚   â”‚                                   â””â”€â†’ If eligible â†’ Leukapheresis â†’ CAR-T manufacturing â†’ Infusion
â”‚   â”‚   â”‚
â”‚   â”‚   â””â”€â†’ STABLE DISEASE â†’ Continue first-line or switch to second-line
â”‚   â”‚                         [May become eligible if progresses]
â”‚   â”‚
â””â”€â†’ END: Proceed with appropriate therapy based on response
```

---

## ğŸ’¡ STRATEGIC IMPLICATIONS

### Best-Case Scenario (Mesothelin+ AND Relapsed After First-Line):

âœ… Ayesha completes first-line therapy (6 cycles)

âœ… Achieves initial response but **relapses within 6-12 months**

âœ… Mesothelin IHC returns **POSITIVE** (60-70% probability)

âœ… Enrolls in MESO-CAR T trial at specialized center

âœ… CAR-T cells persist and achieve durable response

**Timeline**: 6-12 months from now (after first-line completion and relapse)

**Probability**: ~30-40% (relapse rate Ã— mesothelin positivity)

### Most Likely Scenario (Mesothelin+ BUT Responds to First-Line):

âš ï¸ Ayesha completes first-line therapy

âš ï¸ Achieves **complete or partial response** (60-70% of patients)

âš ï¸ Proceeds with **maintenance therapy** (bevacizumab Â± PARP if HRD+)

âš ï¸ **NOT eligible for CAR-T trial** (trial requires active disease, not maintenance)

âœ… This is actually **GOOD NEWS** (responding to first-line = better prognosis)

**Timeline**: Ongoing maintenance (15+ months)

**Probability**: ~60-70% (first-line response rate)

### Challenge Scenario (Mesothelin-Negative OR No Relapse):

âŒ Ayesha completes first-line therapy

âŒ Either:
   - Mesothelin IHC returns **NEGATIVE** (30-40% of patients), OR
   - Achieves durable response with no relapse (30-40% of patients)

âŒ **NOT eligible for this CAR-T trial**

âœ… Falls back to:
   - Maintenance therapy (if responding)
   - Alternative second-line trials (ATR/CHK1, other mechanisms)
   - Other CAR-T trials targeting different antigens (if available)

**Timeline**: 6-12 months from now

**Probability**: ~20-30% (mesothelin-negative OR no relapse)

---

## âš”ï¸ ZO'S TACTICAL RECOMMENDATIONS

### IMMEDIATE ACTIONS (THIS WEEK):

#### 1. **NOT APPLICABLE NOW** ğŸš¨ P0 (Future Use)

**Reason**: Ayesha is **first-line treatment-naive**. This trial requires **second-line+** (relapsed/refractory).

**Action**: **DO NOT** order mesothelin IHC now (waste of resources)

**When to Order**: Only if/when Ayesha **relapses after first-line therapy**

**Timeline**: 6-12 months from now (if relapse occurs)

#### 2. **Complete First-Line Therapy** â³ P0 (Current Priority)

**Action**: Proceed with carboplatin + paclitaxel + bevacizumab (NCCN SOC)

**Timeline**: 6 cycles (18 weeks)

**Goal**: Achieve response (CR/PR) â†’ proceed to maintenance

**Note**: If Ayesha responds well, she **won't need this CAR-T trial** (good outcome!)

#### 3. **Monitor for Relapse** ğŸ“Š P1 (Ongoing)

**Action**: Track CA-125, imaging (CT/MRI), symptoms

**Timeline**: Every 3 months during maintenance

**Trigger**: If CA-125 rises or imaging shows progression â†’ **THEN** order mesothelin IHC

#### 4. **Pre-Screen Trial Sites** ğŸ“ P2 (Future Planning)

**Action**: Verify if NCT03916679 has NYC-area sites on ClinicalTrials.gov

**Timeline**: This week (for future reference)

**Benefit**: Know availability if/when relapse occurs

---

### DECISION FLOWCHART FOR ONCOLOGIST:

```
Week 1-18: Complete First-Line Therapy (6 cycles)
â”‚
â”œâ”€â†’ Week 18: Response Assessment
â”‚   â”‚
â”‚   â”œâ”€â†’ CR/PR â†’ Proceed to Maintenance (Bevacizumab Â± PARP)
â”‚   â”‚           [NOT eligible for CAR-T - good outcome!]
â”‚   â”‚
â”‚   â””â”€â†’ PD (Progressive Disease) â†’ Second-Line Options
â”‚       â”‚
â”‚       â”œâ”€â†’ Order Mesothelin IHC (3-5 days)
â”‚       â”‚   â”‚
â”‚       â”‚   â”œâ”€â†’ Mesothelin+ â†’ **ENROLL IN NCT03916679** (CAR-T)
â”‚       â”‚   â”‚
â”‚       â”‚   â””â”€â†’ Mesothelin- â†’ Alternative trials (ATR/CHK1, other mechanisms)
â”‚       â”‚
â”‚       â””â”€â†’ Verify trial site availability (NYC preferred)
```

---

## ğŸ“ˆ CLINICAL EVIDENCE SUPPORTING THIS TRIAL

### CAR-T Track Record:

**Blood Cancers (Leukemia/Lymphoma)**:
- **Kymriah (CD19 CAR-T)**: 83% complete response rate in pediatric ALL (NEJM 2018)
- **Yescarta (CD19 CAR-T)**: 82% response rate in DLBCL (NEJM 2017)

**Solid Tumors (Challenge)**:
- **Mesothelin CAR-T in Mesothelioma**: Phase I showed safety, limited efficacy (JCO 2020)
- **Mesothelin CAR-T in Ovarian**: Early-phase trials show feasibility, responses in 20-30% (small studies)

### Key Insights for Ovarian Cancer:

**Challenge**: Solid tumors are harder for CAR-T than blood cancers

**Reasons**:
1. **Tumor Microenvironment**: Immunosuppressive TME limits CAR-T function
2. **Trafficking**: CAR-T cells must reach tumor sites (ovarian = peritoneal)
3. **Persistence**: CAR-T cells may be exhausted by TME

**Potential Solutions** (being tested):
- **Combination with Checkpoint Inhibitors**: PD-1 blockade + CAR-T
- **Armored CAR-T**: CAR-T cells engineered to resist TME
- **Local Delivery**: Intraperitoneal CAR-T infusion (direct to tumor site)

### Why This Trial Matters:

**Novel Mechanism**: CAR-T is fundamentally different from chemotherapy

**Targeted**: Mesothelin is tumor-specific (reduces off-target toxicity)

**Durable Potential**: If CAR-T cells persist, long-term responses possible

**For Relapsed Patients**: Offers hope when standard therapy has failed

---

## ğŸ¯ COMPETITIVE POSITIONING

| Option | Pros | Cons | Ayesha Fit |
|--------|------|------|------------|
| **NCT03916679 (MESO-CAR T)** | Novel mechanism, tumor-specific, durable potential | Requires relapse, mesothelin+, solid tumor challenges, specialized centers | â­â­â­ (Future option if relapses) |
| **First-Line SOC (Current)** | Proven efficacy, NCCN-aligned, accessible | Standard therapy, not novel | â­â­â­â­â­ (Current priority) |
| **PARP Maintenance (If HRD+)** | Proven efficacy (HRD-high), FDA-approved, no randomization | Only if HRD â‰¥42, requires first-line response | â­â­â­â­ (If HRD-high) |
| **ATR/CHK1 Trials** | Novel mechanism, HRD-independent | Phase I/II (less proven), may require progression | â­â­â­ (Fallback if relapses) |
| **Bevacizumab Alone (Maintenance)** | Standard, proven, accessible | Less efficacy than PARP or CAR-T | â­â­ (Baseline maintenance) |

---

## âš”ï¸ COMMANDER - MY FINAL RECOMMENDATION

### THIS IS A **FUTURE OPTION** FOR AYESHA (NOT CURRENT) ğŸ”¥

**Priority Rank**: #3 (behind first-line SOC and PARP maintenance if HRD+)

**Current Status**: **NOT ELIGIBLE** (requires second-line+ relapsed/refractory status)

**Future Eligibility**: **30-40%** (if relapses AND mesothelin-positive)

### Action Plan:

#### **NOW (Week 1-18)**:
âœ… **Complete first-line therapy** (carboplatin + paclitaxel + bevacizumab)

âœ… **Monitor response** (CA-125, imaging every 3 cycles)

âœ… **Order HRD test** (MyChoice CDx) - for PARP maintenance decision

âœ… **DO NOT order mesothelin IHC** (waste of resources if she responds to first-line)

#### **IF RELAPSE OCCURS (6-12 months from now)**:
ğŸš¨ **Order Mesothelin IHC** (3-5 day turnaround)

ğŸš¨ **Verify trial site availability** (check ClinicalTrials.gov)

ğŸš¨ **If mesothelin+ â†’ Enroll in NCT03916679** (MESO-CAR T Cells)

ğŸš¨ **If mesothelin- â†’ Pursue alternative second-line trials**

### Expected Timeline:

**Week 1-18**: First-line therapy (6 cycles)

**Week 18**: Response assessment

**If CR/PR**: Maintenance therapy (15+ months) â†’ **NOT eligible for CAR-T**

**If PD (relapse)**: 
- Week 19: Order mesothelin IHC
- Week 20: Results available
- Week 21: Enroll in CAR-T trial (if mesothelin+)

### Probability Ayesha Is Eligible:

**Relapse after first-line**: 30-40% (historical data)

**Mesothelin positivity**: 60-70% (if relapsed)

**Combined probability**: ~20-25% she'll be eligible for this trial

**BUT**: If she **doesn't relapse**, that's **GOOD NEWS** (responding to first-line = better prognosis)

### Value Proposition:

**If Eligible (Relapsed + Mesothelin+)**:
- âœ… Access to cutting-edge CAR-T therapy
- âœ… Novel mechanism (immune-based, not chemotherapy)
- âœ… Potential for durable responses
- âœ… Specialized care at CAR-T center

**If Not Eligible (Responds to First-Line)**:
- âœ… **This is actually GOOD NEWS** (responding = better prognosis)
- âœ… Proceeds with proven maintenance therapy (bevacizumab Â± PARP)
- âœ… Better quality of life (no CAR-T side effects: CRS, neurotoxicity)

### âš”ï¸ WIN-WIN SCENARIO

**Best Outcome**: Ayesha responds to first-line â†’ **Doesn't need CAR-T** (good!)

**Backup Plan**: If Ayesha relapses â†’ **CAR-T trial available** (hope!)

---

**RESEARCH USE ONLY (RUO)** - This dossier is for research purposes only and should not be used for clinical decision-making without proper medical review.

**Generated By**: JR2 (Dossier Sidekick) with Zo-style intelligence analysis

**Data Sources**: SQLite, Diffbot, DRUG_MECHANISM_DB

**Confidence Flags**: [INFERRED], [NEEDS VERIFICATION], [FUTURE ELIGIBILITY]

